 |
      
|
|
|
|
|
|||||
|
|
March 30, 2004
Neurochem to present at 11th Anniversary of Future Leaders in the Biotech Industry. About Neurochem
Neurochem is focused on the development and commercialization of innovative therapeutics for
neurological disorders. The Company's pipeline of proprietary, disease-modifying, oral products
addresses critical unmet medical needs. Fibrillex™, designated an orphan and Fast Track Product
candidate, is in a Phase II/III clinical trial for AA amyloidosis. Alzhemed™ and
Cerebril™ have completed a Phase II clinical trial for Alzheimer's Disease and for the
prevention of hemorrhagic stroke caused by cerebral amyloid angiopathy respectively. For additional
information on Neurochem, please visit our website at: (www.neurochem.com).
Certain statements contained in this news release, other than statements of fact that are independently
verifiable at the date hereof, may constitute forward-looking statements. Such statements, based
as they are on the current expectations of management, inherently involve numerous risks and
uncertainties, known and unknown, many of which are beyond Neurochem's control. Such risks include
but are not limited to: the impact of general economic conditions, general conditions in the
pharmaceutical industry, changes in the regulatory environment in the jurisdictions in which Neurochem
does business, stock market volatility, fluctuations in costs, and changes to the competitive
environment due to consolidation as well as other risks included in public filings of Neurochem.
Consequently, actual future results may differ materially from the anticipated results expressed
in the forward-looking statements. The reader should not place undue reliance on the forward-looking
statements included in this news release. These statements speak only as of the date made and
Neurochem is under no obligation and disavows any intention to update or revise such statements as
a result of any event, circumstances or otherwise.
For further Information, please contact: |
 |
|
 |
|
Our site is best viewed with IE4+ at a resolution of 1024×768. |
|
